Breakthrough results in kidney trials💪

*together w/ StocksToTrade & Paradigm Press

Good day, 360!

Here are some of our top movers today - good news for PROK! And a special invitation to join Tim Bohen live as he debuts… The Oracle 🔮.  »Save your seat HERE «

Be the most enlightened trader on the Street!

FOCUS LIST🔎

PROK - Up over 100% in the pre-market after reporting statistically and clinically significant topline results for the Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes

OCC - Up over 32% in pre after announcing strategic collaboration with Lightera 

EVGN - Up over 5% in pre after announcing completion of transaction for the sale of Lavie Bio's activity to ICL

HOTLIST🔥

PROK - Up over 100% in the pre-market after reporting statistically and clinically significant topline results for the Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes

ProKidney Corp. (PROK) is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

In the pre-market this morning, the company reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes.

Highlights include:

• Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial

• In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the period following the last rilparencel injection. This 4.6 mL/min/1.73m2 per year difference was statistically significant (p<0.001) and clinically meaningful

• In Group 2 (n=25), patients were randomized to receive a single rilparencel injection followed by a second injection only if kidney function worsened and a re-dosing trigger was met. The annual decline in eGFR slope improved by 50% from -3.4 mL/min/1.73m2 in the pre-injection period to -1.7 mL/min/1.73m2 in the period following the last rilparencel injection. This 1.7 mL/min/1.73m2 per year difference was not statistically significant (p=0.085) but suggests evidence of a dose response

• No rilparencel-related serious adverse events were observed; the safety profile was consistent with previously reported study results and comparable to a kidney biopsy

• FDA Type B meeting set for this summer to confirm ProKidney’s approach to using eGFR slope as the surrogate endpoint in the ongoing Phase 3 PROACT 1 study for accelerated approval

Shares of PROK traded up over 100% in the pre-market in reaction to the news.

The $0.82 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.96, $1, $1.10, $1.25, $1.40 and then the pre-market high at $1.52. Beyond that, $1.65, $1.80 and $2 come into play.

Below $0.82, targets to the downside are $0.73 and then a gap fill at $0.6065.

OCC - Up over 32% in pre after announcing strategic collaboration with Lightera

Optical Cable Corporation (OCC) together with its subsidiaries, manufactures and sells fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market in the United States and internationally.

In the after-hours yesterday, the company announced that it and Lightera have entered into a strategic collaboration agreement to expand product offerings and solutions—especially for the data center and enterprise sectors

As a result of this strategic collaboration, OCC and Lightera both expect to benefit from opportunities to capitalize on the ability to offer expanded fiber optic and copper cabling and connectivity solutions to the enterprise sector, the data center sector, as well as an expanded presence in other sectors. T

he companies will combine portions of the extensive product portfolios of both OCC and Lightera to deliver integrated cabling and connectivity solution offerings, which will be sold by OCC.

In connection with this strategic collaboration, Lightera has made an investment in OCC, purchasing shares of OCC common stock from the company and Lightera holding 7.24% of the company's outstanding shares.

Shares of OCC traded up over 32% in the pre-market in reaction to the news.

The $4.50 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $5, $5.44, $6, $6.20, $6.40 and then the pre-market high at $6.95. Beyond that, $7, $8 and $9 come into play.

Below $4.50, targets to the downside are $4, $3.80 and then a gap fill at $3.62.

EVGN - Up over 5% in pre after announcing completion of transaction for the sale of Lavie Bio's activity to ICL 

Evogene Ltd. (EVGN) is a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to drive innovation in life-science product development.

In the pre-market this morning, the company announced the successful completion and closing of the previously disclosed transaction involving the divestiture of the majority of the activities and assets of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. (NYSE: ICL) (TASE: ICL). As part of the transaction, Evogene has also transferred to ICL its proprietary MicroBoost AI for AG platform, which is used to accelerate microbial product development in the agriculture sector.

Pursuant to the definitive agreement originally announced on April 21, 2025, ICL has acquired Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, microbial bank, pipeline of advanced development programs, and current commercial product offerings. In addition, Lavie Bio's core personnel will transfer to ICL. Concurrently, Evogene has divested its MicroBoost AI Tech-Engine for Agriculture, a computational engine designed to optimize microbial discovery and development through artificial intelligence, for additional consideration.

It is important to note that Lavie Bio's existing strategic partnerships and commercial agreements are not part of this transaction and will remain under Lavie Bio's ownership. These agreements may yield future revenues for the benefit of Lavie Bio's shareholders.

Shares of EVGN traded up over 5% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $1.46. Beyond that, $1.50, $1.60, $1.81 and $2 come into play.

Below $1.46, there is a gap to fill at $1.32, with $1.26 below that.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed past the MOON 🌝.  Simply text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.